IPP Bureau
Briefs: Neuland Laboratories, Cipla and Zydus
By IPP Bureau - February 20, 2023
Cipla has received 8 inspectional observations in Form 483
Zydus receives tentative approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets
By IPP Bureau - February 20, 2023
Canagliflozin and Metformin Hydrochloride Tablets had annual sales of US $49.4 million in the United States
India achieves 15,000+ transplants in a year
By IPP Bureau - February 20, 2023
There is a fast resurgence in the transplant activities post COVID
Fluor selected by Agilent for expansion of oligonucleotide manufacturing facility in Colorado
By IPP Bureau - February 19, 2023
Fluor is providing architectural and engineering services and procuring equipment for the new 275,000 square-foot manufacturing facility that will house two manufacturing lines to double manufacturing capability
Merck and AstraZeneca present final results from Phase 3 PROpel Trial
By IPP Bureau - February 18, 2023
Data build on previously reported results from the primary endpoint of investigator-assessed radiographic progression-free survival
USFDA accepts for priority review the sNDA for Merck’s Prevymis
By IPP Bureau - February 18, 2023
FDA also accepts a separate supplemental application to extend prophylaxis with PREVYMIS to 200 days in certain HSCT recipients
IAGES collaborates with technology leaders in robotic surgery
By IPP Bureau - February 18, 2023
IAGES to focus on upskilling and adoption of advanced Minimal Access Surgery technologies in 2023
Garuda Aerospace and Narayana Health join hands to transport biomedical supplies using drone
By IPP Bureau - February 18, 2023
The partnership is announced at Aero India 2023, Bangalore
.png "Pfizer announces Talzenna and Xtandi combination data from phase 3 study")
Pfizer announces Talzenna and Xtandi combination data from phase 3 study
By IPP Bureau - February 18, 2023
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Asahi Kasei completes construction of microcrystalline cellulose plant
By IPP Bureau - February 18, 2023
With the new facility, the company underlines its commitment to meet the substantially growing demand for its MCC
Patient care is an imperative dimension in providing quality healthcare: Dr. Bharati Pravin Pawar
By IPP Bureau - February 18, 2023
The workshop strived to sensitize states and various stakeholder departments regarding their role in the implementation of National Patient Safety Implementation Framework, as well as augment capacity building of health care professionals
Dr. Mandaviya hails eSanjeevani milestone of providing telemedicine services to 10 Cr patients
By IPP Bureau - February 18, 2023
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
Zydus receives final approval from USFDA for Sirolimus Tablets, 1 mg and 2 mg
By IPP Bureau - February 18, 2023
Sirolimus Tablets had annual sales of USD 69 million in the United States (IQVIA MAT Dec. 2022)
Lupin receives EIR from USFDA for injectable facility in Nagpur
By IPP Bureau - February 18, 2023
The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022
Glenmark Pharmaceuticals receives 2nd ANDA tentative approval for Saxagliptin Tablets, 2.5 mg and 5 mg
By IPP Bureau - February 18, 2023
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
